Fatemeh Yarian
Overview
Explore the profile of Fatemeh Yarian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohammadi R, Kazemi B, Yarian F, Moosavian H, Farsinejad A
Naunyn Schmiedebergs Arch Pharmacol
. 2025 Feb;
PMID: 40014126
Prominin-1, or CD133, is a membrane-bound pentaspan protein that has been utilized recently to identify cancer stem cells (CSCs) in a variety of carcinomas. Today, bioinformatics offers a potent tool...
2.
Lakhshei P, Ahangarzadeh S, Yarian F, Koochaki A, Kazemi B, Kiamehr Z, et al.
Adv Biomed Res
. 2024 Oct;
13:46.
PMID: 39411694
Backgrounds: Apoptin can induce tumor cell-specific apoptosis in a broad range of human tumor cells and is a potential anticancer therapeutic candidate to kill tumor cells. Materials And Methods: We...
3.
Mohammadi R, Ghani S, Arezumand R, Farhadi S, Khazaee-Poul Y, Kazemi B, et al.
Curr Mol Med
. 2023 Aug;
24(10):1250-1268.
PMID: 37594115
The application of monoclonal antibodies and antibody fragments with the advent of recombinant antibody technology has made notable progress in clinical trials to provide a regulated drug release and extra...
4.
Ghani S, Bandehpour M, Yarian F, Baghaei K, Kazemi B
Appl Biochem Biotechnol
. 2023 Jul;
196(3):1399-1418.
PMID: 37410352
The pentaspan transmembrane glycoprotein CD133, prominin-1, is expressed in cancer stem cells in many tumors and is promising as a novel target for the delivery of cytotoxic drugs to cancer-initiating...
5.
Ghani S, Rafiee B, Bahrami S, Mokhtari A, Aghamiri S, Yarian F
Int J Prev Med
. 2022 Dec;
13:133.
PMID: 36452468
Background: These days, silver nanoparticles (Ag NPs) have been given considerable attention and applied in medical technology due to their great antimicrobial and antioxidant features. In the present study, we...
6.
Ghani S, Yarian F, Bandehpour M, Kazemi B
Iran J Pharm Res
. 2022 Feb;
20(4):80-91.
PMID: 35194430
The selection of the appropriate fragment of the cell surface receptors as an antigen is significant for the production of antibodies. CD133, as a suitable biomarker candidate in the cancer...
7.
Ghani S, Deravi N, Pirzadeh M, Rafiee B, Rezanejad Gatabi Z, Bandehpour M, et al.
Curr Pharm Biotechnol
. 2021 Aug;
23(8):1061-1071.
PMID: 34375187
Background And Aims: Antibody-based therapeutics have been shown to be promising for the treatment of colorectal cancer patients. However, the size and long-circulating half-lives of antibodies can limit their reproducible...
8.
Nokhodian Z, Ranjbar M, Nasri P, Kassaian N, Shoaei P, Vakili B, et al.
J Res Med Sci
. 2020 Dec;
25:101.
PMID: 33273946
Humans have always been encountered to big infectious diseases outbreak throughout the history. In December 2019, novel coronavirus (COVID-19) was first noticed as an agent causing insidious pneumonia in Wuhan,...
9.
Ghani S, Bahrami S, Rafiee B, Eyvazi S, Yarian F, Ahangarzadeh S, et al.
Life Sci
. 2020 Nov;
265:118791.
PMID: 33220288
Colorectal cancer (CRC) is the fourth most common cause of cancer and mortality worldwide and is the third most common cancer in men and women. Surgery, radiotherapy, and chemotherapy are...
10.
Rafighdoust H, Ahangarzadeh S, Yarian F, Taheri R, Lari A, Bandehpour M, et al.
Iran J Basic Med Sci
. 2020 Sep;
23(8):1053-1058.
PMID: 32952952
Objectives: We previously conducted an research on the interactions between the ribosome display-selected single chain variable fragment (scFv) and factor H binding protein (fHbp) of . We found that heavy...